Therapy News and Research

RSS

Evolocumab fails to reduce vein graft disease after coronary artery bypass surgery

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in Lancet.

3 Sep 2025

New protein-based therapeutic tool could change the way we treat diseases

A team of scientists at Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) has created a protein-based therapeutic tool that could change the way we treat diseases caused by harmful or unnecessary cells.

3 Sep 2025

Long-term benzodiazepine use linked to poor sleep quality in older adults

Long-term use of benzodiazepine and related drugs has been linked to poorer quality sleep in older adults with insomnia.

3 Sep 2025

Sugar-coated nanoparticles offer new hope for treating triple-negative breast cancer

Triple-negative breast cancer is particularly aggressive and difficult to treat; but recent research may offer a new way to target the often-deadly disease.

3 Sep 2025

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents.

3 Sep 2025

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

3 Sep 2025

Early aspirin discontinuation safe after complete revascularization in acute MI

Among low-risk patients with acute MI who underwent early complete revascularization and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse cardiovascular and cerebrovascular events, while reducing bleeding risk.

3 Sep 2025

Faster progression to severe diabetes observed in people with learning disabilities

People with learning disabilities progress faster to severe type 2 diabetes and are at greater risk of dying from their condition than people without these disabilities, suggests research published in the open access journal BMJ Open Diabetes Research & Control.

2 Sep 2025

AI scans arteries and predicts risk after heart attack better than traditional review

Researchers found that AI applied to OCT imaging can standardize detection of thin-cap fibroatheroma (TCFA) and identify post–heart attack patients at higher two-year risk. Whole-segment AI analysis outperformed lesion-focused human review, offering stronger prognostic value and reassurance for low-risk patients.

2 Sep 2025

Most adults experience dental fear and show interest in virtual fear-treatments

Nearly three out of four adults fear going to the dentist, according to a new study published in the Journal of the American Dental Association.

2 Sep 2025

New drug dismantles cancer cell powerhouse to halt tumor growth

Researchers at MUSC Hollings Cancer Center have discovered a potentially powerful weapon in the fight against head and neck cancers.

2 Sep 2025

Breakthrough discovery reveals treatable form of familial mesothelioma

Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of mesothelioma that may lead to more successful treatments.

2 Sep 2025

Platelets found to mop up DNA fragments and improve early cancer detection

Platelets are probably best known for their role in blood clotting, making scabs and related, if less salubrious, contributions to heart attacks and strokes.

2 Sep 2025

Electrical stimulation reprograms macrophages to reduce inflammation

Scientists from Trinity College Dublin have discovered that electrically stimulating "macrophages" – one of the immune systems key players – can "reprogramme" them in such a way to reduce inflammation and encourage faster, more effective healing in disease and injury.

2 Sep 2025

MicroRNA panels show promise for improving prostate cancer diagnosis

Prostate cancer is highly heterogeneous, ranging from slow-growing tumors to aggressive, life-threatening disease.

2 Sep 2025

Dormant tumor cells targeted to reduce breast cancer relapse

A first-of-its-kind, federally funded clinical trial has shown it's possible to identify breast cancer survivors who are at higher risk of their cancer coming back due to the presence of dormant cancer cells and to effectively treat these cells with repurposed, existing drugs.

2 Sep 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

ESC and EAS release new dyslipidaemia guidelines

The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) have just published the new international recommendations for managing dyslipidaemias. They were presented at the Annual Cardiology Congress held in Madrid from August 29th to September 1st, 2025.

2 Sep 2025

Dual antiplatelet therapy after heart bypass surgery offers no added benefit over aspirin alone

Dual antiplatelet therapy after heart bypass surgery is not more effective than aspirin alone - and it increases the risk of excessive bleeding. This has now been shown in a study of 2,201 patients at 22 Nordic heart surgery units.

1 Sep 2025

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States.

1 Sep 2025

Therapy News and Research

Evolocumab fails to reduce vein graft disease after coronary artery bypass surgery

New protein-based therapeutic tool could change the way we treat diseases

Long-term benzodiazepine use linked to poor sleep quality in older adults

Sugar-coated nanoparticles offer new hope for treating triple-negative breast cancer

Novel vascularized cancer-on-a-chip model reflects the microenvironment of liver tumors

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Early aspirin discontinuation safe after complete revascularization in acute MI

Faster progression to severe diabetes observed in people with learning disabilities

AI scans arteries and predicts risk after heart attack better than traditional review

Most adults experience dental fear and show interest in virtual fear-treatments

New drug dismantles cancer cell powerhouse to halt tumor growth

Breakthrough discovery reveals treatable form of familial mesothelioma

Platelets found to mop up DNA fragments and improve early cancer detection

Electrical stimulation reprograms macrophages to reduce inflammation

MicroRNA panels show promise for improving prostate cancer diagnosis

Dormant tumor cells targeted to reduce breast cancer relapse

Aptamer signs therapeutic development agreement with Invizius

ESC and EAS release new dyslipidaemia guidelines

Dual antiplatelet therapy after heart bypass surgery offers no added benefit over aspirin alone

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News